Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line

Gemma, Akihiko; Takenaka, Kiyoshi; Hosoya, Yoko; Matuda, Kuniko; Seike, Masahiro; Kurimoto, Futoshi; Ono, Yasushi; Uematsu, Kazutsugu; Takeda, Yuichiro; Hibino, Suguru; Yoshimura, Akinobu; Shibuya, Masabumi; Kudoh, Shoji

doi:10.1016/s0959-8049(01)00154-x

Cited by 83 publications

(75 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, Gemma et al (2001) compared the expression profiles of two subpopulations of an adenocarcinoma cell line with high metastatic potential -PC9/f9 and PC9/f14 -with the parent cell line PC9 using cDNA array. They have shown that the expression of matrix metalloproteinase-2 (MMP-2), plasminogen activator inhibitor-1 (PAI-1) and IL-1 alpha was overexpressed in the highly metastatic subpopulations.…”

Section: Discussionmentioning

confidence: 99%

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines

et al. 2003

View full text Add to dashboard Cite

Despite advances in the management of solid tumours, the development of metastases continues to be the most significant problem and cause of death for cancer patients. To define genetic determinants of pulmonary metastases, we have applied oligonucleotide microarrays to established murine models of highly metastatic D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. These models are characterised by primary subcutaneous growth in C57BL/6J mice, a period of minimal residual disease and spontaneous pulmonary metastases. Microarray analysis defined seven genes, namely -arginase, brain natriuretic peptide (BNP), interleukin-1 alpha (IL-1 alpha), plasminogen activator inhibitor-2 (PAI-2), surfactant protein C (SP-C), uteroglobin (UG) and wnt-1-induced secreted protein-1 (WISP-1), which were consistently elevated in pulmonary metastases compared to the primary tumour of both D122 and B16-F10.9 models. Previous studies demonstrated that two of these seven genes, IL-1 alpha and PAI-2, are involved in the metastatic process. The results obtained by the microarrays were confirmed by real-time quantitative PCR, for three chosen genes -PAI-2, WISP-1 and UG. Our approach aimed to identify genes essential for the metastatic process in general and for pulmonary metastases specifically. Further research should address the precise role of these genes in the metastasising process to the lungs and test if they could be used as targets for future therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines

et al. 2003

View full text Add to dashboard Cite

show abstract

“…PC9/f9 (Takenaka et al, 2000) and PC9/f14 (Gemma et al, 2001) are highly metastatic sublines of PC9 established at Nippon Medical School using artificial metastasis methods. In an attempt to elucidate potential mechanisms of resistance to gefitinib, we evaluated cDNA expression profiles and their relationship to gefitinib resistance.…”

Section: Cell Linesmentioning

confidence: 99%

“…Messenger RNA was then purified from total RNA by incubation with oligo-dT-magnetic beads (Toyobo Co., Osaka, Japan). The ElectorGene Array System (GeneticLab Co. Ltd, Sapporo, Japan) was used for filter-based cDNA array analysis, as previously reported (Gemma et al, 2001). In this analysis, 1300 species of human DNA fragments, including cancer-related and drugresistance-associated genes, as well as housekeeping and nonmammalian genes as negative controls, are spotted in duplicate on a filter.…”

Section: Drugs and Growth-inhibition Assaymentioning

confidence: 99%

See 1 more Smart Citation

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)

et al. 2005

View full text Add to dashboard Cite

Gefitinib (IRESSA), an epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor, has antitumour activity in the advanced non-small-cell lung cancer (NSCLC) setting. However, in chemotherapy-naïve patients with advanced NSCLC, the addition of gefitinib to standard chemotherapy regimens failed to increase survival. These results suggest the need for improved patient selection and combination rationales for targeted therapies. We have identified subpopulations of an adenocarcinoma cell line that are naturally resistant to gefitinib, and have analysed the cDNA expression profiles, genomic status of EGFR gene and the effect of gefitinib on signalling pathways in these cell lines in order to identify key mechanisms for naturally acquired resistance to gefitinib. Gefitinib-resistant subpopulations demonstrated increased Akt phosphorylation (not inhibited by gefitinib), reduced PTEN protein expression and loss of the EGFR gene mutation when compared with parental cell lines. These differences in Akt and PTEN protein expression were not evident from the cDNA array profiles. These data suggests that (1) the EGFR gene mutation may be possibly lost in some cancer cells with other additional mechanisms for activating Akt, (2) reintroduction of PTEN or pharmacological downregulation of the constitutive PI3K -Akt-pathway activity may be an attractive therapeutic strategy in cancers with gefitinib resistance.

show abstract

“…A number of studies have reported that high IL-1 concentrations within the tumour microenvironment are associated with a more virulent tumour phenotype. For example, solid tumours in which IL-1 has been shown to be upregulated include melanomas, colon, lung, head and neck cancers, and patients with high IL-1 producing tumours have generally bad prognoses [6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

IL‐1 family in breast cancer: Potential interplay with leptin and other adipocytokines

2008

View full text Add to dashboard Cite

Edited by Masayuki MiyasakaKeywords: IL-1 Leptin Adipocytokine Breast cancer Obesity a b s t r a c t Obesity is associated with an increased risk of breast cancer. interleukin-1 (IL-1), a pro-inflammatory cytokine secreted by adipose tissue, is involved in breast cancer development. There is also convincing evidence that other adipocytokines including leptin not only have a role in haematopoiesis, reproduction and immunity but are also growth factors in cancer. Therefore, IL-1 family and leptin family are adipocytokines which could represent a major link between obesity and breast cancer progression. This minireview provides insight into recent findings on the prognostic significance of IL-1 and leptin in mammary tumours, and discusses the potential interplay between IL-1 family members and adipocyte-derived hormones in breast cancer.

show abstract

Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line

Cited by 83 publications

References 31 publications

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines

Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines

Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA)

IL‐1 family in breast cancer: Potential interplay with leptin and other adipocytokines

Contact Info

Product

Resources

About